Role of Immunotherapy in Advanced Gastroesophageal Cancer

Gretel Terrero, A. Craig Lockhart

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations


Purpose of Review: Immunotherapy and tumor microenvironment have been at the forefront of cancer research over the past several decades. Here, we will review the role of immunotherapy in advanced gastroesophageal cancers including targeted antibodies, immunomodulating agents, vaccines, oncolytic virus therapy, and adoptive immunotherapy, and discuss the future direction for immunotherapy in this population. Recent Findings: Targeted antibodies are already standard-of-care. An anti-PD-1 monoclonal antibody is currently FDA approved for second-line treatment of locally advanced or metastatic ESCC, as well as beyond second-line treatment of advanced G/GEJ cancers, and recent data suggests it may be considered in first-line treatment of advanced G/GEJ cancers. Combination therapies such as immunotherapy plus chemotherapy and/or radiotherapy, vaccines, oncolytic viral therapy, and adoptive immunotherapy in varying combinations are currently under active investigation. Summary: Several trials are ongoing and are hoped to reach more efficacious and individualized treatment options in advanced gastroesophageal cancer, where novel treatment options are desperately needed.

Original languageEnglish (US)
Article number112
JournalCurrent oncology reports
Issue number11
StatePublished - Nov 1 2020


  • Advanced esophageal cancer
  • Advanced gastric cancer
  • Advanced gastroesophageal cancer
  • Immunotherapy
  • PD-1
  • PD-L1

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Role of Immunotherapy in Advanced Gastroesophageal Cancer'. Together they form a unique fingerprint.

Cite this